Lumos Diagnostics FY22 First Half Year Results
Filed with ASX · · 4 pages · English
• FebriDx® application for regulatory clearance in the U.S. remains on track for decision from the FDA in H2 FY2022. • Cash 31 December 2021 US$10.5 million Melbourne, VIC. (28 February 2022)-Lumos Diagnostics(ASX:LDX, “Lumos” or the “Company”), a leader in rapid point-of-care (POC) diagnostic technologies, today has announced its financial results for the FY2022 half year ending 31 December 2021.
Lumos Diagnostics Holdings Ltd. on 6ix
Earlier from Lumos Diagnostics
- Change To Lumos Board
- Victorian Government Intent for Lumos Manufacturing Hub
- Over 100 Pharmacies in Liverpool UK Launch FebriDx Service
- Lumos Provides ViraDx and FebriDx Regulatory Update
- Lumos Receives Initial Orders for CoviDx In Canada
Later from Lumos Diagnostics
- FY2022 Half Year Update
- FebriDx Update - Brazil Market Authorisation & New Study
- Operational Review & Management Reorganisation
- Operational Update and Accelerated Entitlement Offer
- Target Market Determination
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics